UNIQURE NV's ticker is QURE and the CUSIP is N90064101. A total of 175 filers reported holding UNIQURE NV in Q1 2022. The put-call ratio across all filers is 0.32 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $208 | -99.9% | 10,342 | -34.5% | 0.00% | -50.0% |
| Q3 2022 | $296,000 | -37.6% | 15,791 | -37.9% | 0.00% | -20.0% |
| Q2 2022 | $474,000 | +0.2% | 25,447 | -2.7% | 0.01% | +66.7% |
| Q1 2022 | $473,000 | -16.0% | 26,165 | -3.7% | 0.00% | 0.0% |
| Q4 2021 | $563,000 | -41.0% | 27,164 | -8.8% | 0.00% | -25.0% |
| Q3 2021 | $954,000 | +86.7% | 29,798 | +79.6% | 0.00% | +100.0% |
| Q2 2021 | $511,000 | -47.0% | 16,595 | -42.0% | 0.00% | -60.0% |
| Q1 2021 | $965,000 | +114.4% | 28,635 | +130.0% | 0.01% | +150.0% |
| Q4 2020 | $450,000 | -26.8% | 12,452 | -25.4% | 0.00% | -50.0% |
| Q3 2020 | $615,000 | +69.9% | 16,685 | +118.5% | 0.00% | +33.3% |
| Q1 2020 | $362,000 | -26.0% | 7,636 | +11.9% | 0.00% | -25.0% |
| Q4 2019 | $489,000 | +119.3% | 6,821 | +139.4% | 0.00% | +100.0% |
| Q2 2019 | $223,000 | +87.4% | 2,849 | -52.9% | 0.00% | +100.0% |
| Q4 2017 | $119,000 | – | 6,055 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 155,500 | $11,803,000 | 2.66% |
| Aquilo Capital Management, LLC | 901,490 | $16,290,000 | 2.39% |
| Nantahala Capital Management | 2,811,459 | $50,803,000 | 2.25% |
| Privium Fund Management B.V. | 493,229 | $8,913,000 | 1.97% |
| 683 Capital Management, LLC | 1,355,000 | $24,485,000 | 1.31% |
| Henry James International Management Inc. | 125,622 | $2,270,000 | 0.90% |
| Integral Health Asset Management, LLC | 170,000 | $3,072,000 | 0.80% |
| Nantahala Capital Management | 890,000 | $16,082,000 | 0.71% |
| Sonic Fund II, L.P. | 50,000 | $904,000 | 0.51% |
| Voss Capital, LLC | 70,000 | $1,265,000 | 0.40% |